期刊文献+

全身热疗法治疗晚期肝脏恶性肿瘤39例报告

Whole Body Hyperthermia in Treatment of 39 Cases of Advanced Hepatic Carcinoma
下载PDF
导出
摘要 目的 探讨全身热疗法(whole body hyperthermia,WBH)治疗肝脏恶性肿瘤的疗效及其对肝功能的影响。方法 采用WBH治疗肝脏恶性肿瘤患者39例,并对治疗前、后患者肝功能指标进行动态观察,分析该疗法对肝脏功能的影响,并通过分析治疗效果,初步评估该疗法的疗效。结果 ①WBH治疗不能手术切除的晚期肝脏恶性肿瘤患者的有效率为61.5%(24/39),60.0%(9/15)的患者AFP有不同程度下降,肿瘤疼痛缓解率达100%;存活期〉2年者占12.8%(5/39),〉1年者占59.0%(23/39),〉6个月者占76.9%(30/39)。②谷丙转氨酶于治疗后1~3d出现明显升高(P〈0.05),7d后下降并接近治疗前水平;谷草转氨酶于治疗后1d明显升高(P〈0.05),3~7d则下降并接近治疗前水平;白蛋白于治疗后1d出现下降(P〈0.05),但3d即已恢复;肝功能正常组总胆红素于治疗后第1~3d出现升高(P〈0.05),而肝功能异常组未观察到同样变化;转肽酶则无明显变化。结论 WBH能改善晚期肝脏恶性肿瘤患者的预后,提高生存质量,延长生存时间,但同时可造成患者肝功能一定程度的可逆性损害。 Objective To evaluate the efficacy of whole body hyperthermia (WBH) in the treatment of advanced hepatic carcinoma and its effect on liver function. Methods From 2001 to 2004, 39 cases of advanced hepatic carcinoma were treated with WBH. The effect of WBH on liver function was assessed by liver function test before and after treatment. Results ① The effective rate of WBH was 61.5 % (24/39) in the treatment of advanced hepatic carcinoma with declined AFP in 60.0% (9/15) of patient and 100% of patients had pain relieve. The survival rates of 6 months, 1 year and 2 years were 76.9% (30/39), 59.0% (23/39) and 12.8% (5/39), respectively. ②Alanine aminotransferase (ALT) elevated obviously in 1-3 d after treatment (P〈0.05), and then approached to its baseline in 7 d. Aspartate aminotransferase (AST) increased significantly 1 d after treatment (P〈0.05) ,and then back to its baseline in 3-7 d. Albumin (ALB) appeared dropped 1 d after treatment (P〈0.05), and restored normally in 3 d. The levels of total bilirubin (TBIL) and gamma glutamyl transpeptidase (GGT) had no evident significant change with the WBH treatment in abnormal liver function group, but TBIL increased 1-3 d after treatment in normal liver function group (P〈0.05). Conclusion In the treatment of advanced hepatic carcinoma, WBH can improve the patients' life quality and prolong their life expectancy. Meanwhile, it could also result in reversible impairment of liver function.
出处 《中国普外基础与临床杂志》 CAS 2006年第2期175-177,共3页 Chinese Journal of Bases and Clinics In General Surgery
关键词 热疗 全身热疗法 肝脏恶性肿瘤 Hyperthermia Whole body hyperthermia Malignant hepatoma
  • 相关文献

参考文献7

  • 1Manjili MH, Wang XY, Park J, et al. Immunotherapy of cancer using heat shock proteins [J]. Front Biosci, 2002,1(7):43
  • 2Sawaji Y, Sato T, Takeuchi A, et al. Anti-angiogenic action of hyperthermia by suppressing gene expression and production of tumour-derived vascular endothelial growth factor in vivo and in vitro [J]. Br J Cancer, 2002,86(10) : 1597
  • 3Sawaji Y, Sato T, Seiki M, et al. Heat shock-mediated transient increase in intracellular 3', 5'-cyclic AMP results in tumor specific suppression of membrane type 1-matrix metalloproteinase production and progelatinase A activation [J]. Clin Exp Metastasis, 2000,18(2) : 131
  • 4Wiedemann GJ, Robins HI, Katschinski DM, et al. Systemic hyperthermia and ICE chemotherapy for sarcoma patients: rationale and clinical status [J]. Anticancer Res, 1997,17(4B) :2899
  • 5Hildebrandt B, Wust P, Ahlers O, et al. The cellular and molecular basis of hyperthermia [J]. Crit Rev Oncol Hematol,2002; 43(1):33
  • 6Katschinski DM, Wiedemann GJ, Longo W, et al. Whole body hyperthermia cytokine induction: a review, and unifying hypothesis for myeloprotection in the setting of cytotoxic therapy [J].Cytokine Growth Factor Rev, 1999,10(2):93
  • 7叶小鸣,黄文起,程权永,朱易凡,左继东,康亮.体外循环全身热灌注疗法治疗恶性肿瘤81例报告[J].中国实用外科杂志,2006,26(1):51-54. 被引量:8

二级参考文献11

  • 1郭起浩,张明园,李柔冰,何燕玲,R.Katzman,D.Salmon.神经心理测验和轻性痴呆[J].中国临床心理学杂志,1996,4(3):132-134. 被引量:6
  • 2McKeating EG, Andrews PJ, Mascia L. Relationship of neuro specific enolase and protein S - 100 concentrations in systemic and jugular venous serum to injury severity and outcome after traumatic brain injury. Acta Neurochir Suppl ( Wien), 1998.117 - 119.
  • 3Hans P. Biochemical markers of the brain injury [ J ]. Agressologie,1988,29(4) :233 -235.
  • 4Manjili MH, Wang XY, Park J, et al. Immunotherapy of cancer using heat shock proteins [ J ]. Front Biosci, 2002,1 ( 7 ) :43 - 52.
  • 5Sawaji Y, Sato T, Takeuchi A, et al. Anti -angiogenic action of hyperthermia by suppressing gene expression and production of tumour- derived vascular endothelial growth factor in vivo and invitro[ J]. Br J Cancer,2002,86(10) :1597 -1603.
  • 6Sawaji Y,Sato T,Seiki M, et al. Heat shock - mediated transient increase in intracellular3',5 '- cyclic AMP results in tumor specific suppression of membrane type 1 - matrix metalloproteinase production and progelatinase A activation[ J ]. Clin Exp Metastasis,2000,18(2) :131 - 138.
  • 7Wiedemann GJ, Robins HI, Katschinski DM, et al. Systemic hyperthermia and ICE chemotherapy for sarcoma patients:rationale and clinical status [ J ]. Anticancer Res, 1997,17 ( 4 B ) : 2899 - 2902.
  • 8Hildebrandt B ,Wust P,Ahlers O,et al. The cellular and molecular basis of hyperthermia[ J]. Crit Rev Oncol Hematol,2002,43(1) :33 -56.
  • 9Katschinski DM,Wiedemann GJ, Longo W, et al. Whole body hyperthermia cytokine induction:a review,and unifying hypothesis for myeloprotection in the setting of cytotoxic therapy [ J ].Cytokine Growth Factor Rev, 1999,10(2 ) :93 -97.
  • 10Parks L,Smith GV. Systemic hyperthermia by extracorporeal induction : techniques and results [ A ]. In : FK Storm. Hyperthermia in Cancer Therapy[ M]. 1983. 401 -44.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部